Editor's key points † The authors review the evolving usage of cryoprecipitate, noting the uncertainty of appropriate dosing and optimal administration. † They call for randomized controlled trials to help guide the use of cryoprecipitate and current, alternative therapeutic options.
within 8 h of collection 11 ). FFP is thawed at 1-68C and centrifuged to remove the supernatant. The remaining insoluble precipitate, which is enriched with clotting factors, is re-suspended in plasma and refrozen at 2188C or colder. Alternatively, cryoprecipitate can be made from FP24, plasma which is frozen within 24 h of collection.
11
Although cryoprecipitate is commonly believed to contain the majority of fibrinogen from plasma, in fact it contains only 32%; the rest remains in the cryosupernatant. 12 However, because cryoprecipitate is re-suspended in a relatively small volume, it contains fibrinogen at a higher concentration than in plasma, although the actual concentration of fibrinogen in cryoprecipitate varies widely ( 3-30 g litre 21 ) because of variability between donors and institution-specific practices (Table 1) . For example, one recent study measured the fibrinogen concentration of 11 different units of cryoprecipitate prepared in the same hospital; 25 Cryoprecipitate therapy
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Cryoprecipitate is usually prepared as a small pool from multiple donors rather than being issued in single units. In a recent UK report, 334 of 423 episodes treated with cryoprecipitate were treated with pooled cryoprecipitate. 34 However, the rate of pooling in other countries is unknown. Typically, five single units are pooled into one bag before issue. A commonly used adult dose is two pools (10 single units) of cryoprecipitate, 28 35 which should increase plasma fibrinogen levels by 1 g litre
21
, 36 depending on the clinical setting.
Pooling of cryoprecipitate can be performed before freezing by the central blood bank 6 or after thawing by licensed centres. 16 Centres in the EU must be licensed under the European Union Blood Directive, which in the UK includes only 20% of laboratories. 37 Furthermore, licensed centres are subject to tight regulations, which has contributed to many facilities abandoning the practice of pooling cryoprecipitate. 38 At licensed centres pooling may be performed upon thawing, either by the blood bank or at the bedside. Each method leads to a delay, either before or after the treating physician receives the blood product from the blood bank, and the optimal method of pooling has not been investigated. 18 24 In addition, there have been concerns regarding how effectively the relatively low volume of cryoprecipitate is removed from bags during the pooling process. 39 The freezing and thawing of plasma during the preparation process generates platelet membrane microparticles, which are concentrated by cryoprecipitation; the microparticle concentration of cryoprecipitate is 265-fold greater than that of the source plasma. 18 These microparticles have been found to contain glycoproteins which are able to interact with fibrinogen, platelets, von Willebrand factor, and other proteins, and this interaction may be enhanced by cryoprecipitation. 40 However, it is unknown whether these microparticles retain haemostatic function after freezing and thawing. Further studies are needed to determine their role in haemostasis, and to understand their potential role in adverse reactions to cryoprecipitate, such as immune reactions and thrombosis. In addition, a recent study has shown that the observable clots that are, in very rare cases, present in thawed cryoprecipitate pools are formed of both cross-linked (soluble) and non-cross-linked (insoluble) fibrin. 41 This study highlights the importance of filtration as a step in the blood collection process to protect patients from the potential harmful effects of transfusion of a blood product in which clots have already formed. 
Clinical settings with acquired coagulopathy
Obstetric patients
Acquired hypo-or afibrinogenaemia in pregnancy and consequent obstetric bleeding represents historically the first indication for fibrinogen supplementation in a non-congenital fibrinogen deficiency and was described as a case report in the literature by Moloney and colleagues in 1949. 49 Fibrinogen supplementation in this patient was done using Cohn Fraction I, 50 . 62 The 2013 European guidelines 56 also mention that empirical use of fibrinogen concentrate in bleeding patients (8-33% obstetric) has indicated potential reductions in blood loss and transfusion requirements, while studies investigating cryoprecipitate in obstetric patients were not identified at the time of writing of these guidelines.
Cardiac surgery
A small number of studies have examined the use of cryoprecipitate in cardiac surgery. In one study, 63 30 patients undergoing thoracic aortic surgery were treated with FFP alone or FFP plus cryoprecipitate. Patients administered with cryoprecipitate experienced significantly less blood loss and required significantly fewer units of FFP. In another study, results of the thromboelastometry (ROTEM) fibrin-based assay (FIBTEM) during cardiopulmonary bypass were successfully used to predict cryoprecipitate transfusion requirement after reversal of protamine. 64 Another recent study found that administration of cryoprecipitate in 13 patients undergoing aortic surgery with deep hypothermic circulatory arrest raised mean plasma fibrinogen levels from 1.54 to 1.93 g litre
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(P¼0.01), and FIBTEM clot amplitude at 10 min (A10) from 3.5 to 5.8 mm (P¼0.04). 25 In vivo recovery of fibrinogen, which indicates the percentage actual increase in plasma fibrinogen level compared with the expected increase after cryoprecipitate administration, was 61.6%. A retrospective analysis of patients receiving blood transfusions during cardiac surgery found that cryoprecipitate transfusion was independently associated with increased 5-yr mortality when compared with a non-transfused matched control group. 65 
Liver disease
One study investigated the use of cryoprecipitate for acquired hypofibrinogenaemia after massive haemorrhage in LT. 66 The study found that intraoperative transfusion of cryoprecipitate was associated with biliary complications, a significant source of patient morbidity and mortality in patients undergoing LT. The authors concluded that cryoprecipitate should only be used in this setting after careful consideration.
In patients with liver disease, the efficacy of cryoprecipitate was compared with that of FFP. 67 Seventeen patients received either 4 U FFP or 5 U cryoprecipitate. Although cryoprecipitate improved coagulopathy, 4 U FFP were more efficacious, produced a significantly greater improvement in international normalized ratio and activated partial thromboplastin time parameters, and resulted in less exposure to blood products than 5 U cryoprecipitate. Patients with liver disease often have multiple deficiencies of both procoagulant and anticoagulant factors. FFP contains both procoagulant and anticoagulant factors at close to normal or below normal concentrations, which may suggest that FFP is more suitable than cryoprecipitate for haemostatic therapy in these patients. At the same time, it must be kept in mind that transfusion may aggravate portal hypertension in these patients, and may paradoxically result in an increased bleeding tendency. 68 Therefore, the matter of the choice of haemostatic agent in this setting is still under debate.
Commercial fibrinogen preparations
Purified, pasteurized fibrinogen concentrate offers an alternative to cryoprecipitate for fibrinogen supplementation therapy, and two recent studies directly compared the efficacy of these two therapies. 9 33 The first report involved 100 transfusion episodes where either cryoprecipitate or fibrinogen concentrate were administered to patients with acquired hypofibrinogenaemia from a variety of clinical settings. 33 For patients administered with two pools of cryoprecipitate (10 U, corresponding to 1.8-2.2 g fibrinogen) the mean increase in plasma fibrinogen post-infusion was 0.26 g litre 21 , when compared with 0.44 g litre 21 for patients administered with 2 g fibrinogen concen-
trate. In addition, in 7 of 64 episodes where cryoprecipitate was administered, plasma fibrinogen levels decreased after infusion. 33 The second report was a retrospective study assessing the impact of the legislated replacement of cryoprecipitate with fibrinogen concentrate in Ireland in 2009, in the setting of major obstetric haemorrhage (MOH). 9 Blood product utilization and clinical outcome were assessed in 77 women with MOH during a 2.5-yr study period. A total of 14 women received cryoprecipitate and 20 received fibrinogen concentrate to treat hypofibrinogenaemia; haemostasis was successfully achieved in all cases. The correlation between dose and subsequent plasma fibrinogen level was stronger for fibrinogen concentrate than for cryoprecipitate. Mean estimated blood loss, RBC transfusion, and plasma transfusion were lower in the fibrinogen group than in the cryoprecipitate group. Together, these results suggest that fibrinogen concentrate is at least as efficacious as cryoprecipitate in increasing plasma fibrinogen concentration, as a haemostatic agent in this setting, or both. A recent prospective, randomized, placebocontrolled study of patients undergoing elective cardiac surgery showed that patients administered with fibrinogen concentrate required significantly fewer allogeneic blood product transfusions when compared with patients in the placebo group (2 U vs 13 U, respectively). 69 Moreover, total avoidance of transfusion was achieved in nearly half of patients who received fibrinogen concentrate, vs none who had received placebo. Given that fibrinogen concentrate has a superior safety profile with regard to transmission of infectious diseases and a smaller transfusion volume, fibrinogen concentrate may be preferable as haemostatic therapy compared with cryoprecipitate. In summary, despite the use of cryoprecipitate in current strategies to treat acquired coagulopathy and the current level of acceptance across a range of clinical settings, surprisingly few trials have examined its efficacy. Therefore, few conclusions can be drawn regarding its effectiveness. Large randomized controlled trials are urgently required to assess the efficacy of cryoprecipitate in correcting afibrinogenaemia and coagulopathy in patients with acquired bleeding. Such studies should take care to eliminate survivor bias (where patients who live longer have a greater probability of receiving treatment, leading to a false association between treatment and survival) and should compare the efficacy of cryoprecipitate with alternative approaches for fibrinogen replacement.
Safety
Few reports have described the rate of adverse events associated with cryoprecipitate, but results from a haemovigilance scheme in Quebec reported 6.57 events per 10 000 U (from a total of 13 692 U administered). 70 Typical adverse events associated with the administration of cryoprecipitate include transmission of infectious diseases, transfusion-associated circulatory overload (TACO), and transfusion-related acute lung injury (TRALI). In a haemovigilance report in the UK from 1996 to 2003, the risk of TRALI was estimated at 1 in 317 000 U of cryoprecipitate issued, 71 although this may be a conservative estimate as TRALI is commonly underdiagnosed. 72 In the 2011 Serious Hazards of Transfusion report, only one incidence of an acute transfusion reaction was reported in the UK; the patient suffered from urticaria and a sudden decrease in cardiac output. 73 There have also been reports implicating cryoprecipitate in cases of acute anaphylactic shock, pulmonary oedema, intravascular haemolysis, and biliary complications. 42 66 74 FFP transfusion in non-massively transfused trauma patients has been shown to be associated with adverse events in a dosedependent manner; 75 the same can be assumed to be true for cryoprecipitate. However, given that an adult dose of cryoprecipitate of 10 U is sourced from multiple donors, it carries a greater risk of viral transmission per dose. 18 The risk of viral infection with cryoprecipitate is higher than that of fibrinogen concentrate, despite fibrinogen concentrate being produced from a larger donor pool, because the production of fibrinogen concentrate involves numerous stringent steps including pasteurization, adsorption, and precipitation, which remove or inactivate a wide range of enveloped and non-enveloped viruses. 76 77 In most of the few countries in which it is still available, cryoprecipitate is no longer used as a treatment for haemophilia because of the lack of anti-viral processing. Although the lifetime exposure for patients with acquired bleeding is less than for patients with haemophilia, in our view its continued use in surgical settings and acquired bleeding nevertheless represents a double standard. 8 78 79 Cryoprecipitate has been accepted into general use as it has been used for many years, despite the absence of evidence to confirm efficacy and rigorous clinical proof of safety, as is currently required for the approval of new biological therapies. Given that cryoprecipitate is not virus-inactivated, is a pooled product, there is a lack of evidence demonstrating its efficacy and there are potentially safer alternatives currently available, it is unlikely that regulatory approval for its use would be granted today. 80 
Current licensing and regulatory status
Currently, cryoprecipitate is licensed for use in certain indications in the UK, the USA, Canada, Australia, and New Zealand; however, it has been withdrawn from use in most of Western Europe because of safety concerns. Cryoprecipitate was also recently withdrawn from use in Ireland, where fibrinogen concentrate is now used for fibrinogen supplementation in its place, despite a lack of formal licensing. Country-specific guidelines and recommendations for the content and use of cryoprecipitate are outlined in 48 The American
Association of Blood Banks 90 recommends dosing according to the following formulae to achieve a specific increase in plasma fibrinogen levels: Over the last 20 yr, clinical indications for the use of cryoprecipitate have changed because of several reasons; namely, a better understanding of haemostasis and coagulopathy and the critical role of fibrinogen levels in these processes, increased awareness of pathogen transfer and other sideeffects associated with allogeneic blood products, and the introduction of alternative therapies such as coagulation factor concentrates. Currently, guidelines from the USA, Canada, the UK, and Australia are generally united in recommending the use of cryoprecipitate to treat acquired afibrinogenaemia where fibrinogen levels are diagnosed as falling below a set threshold, usually ,1.0 g litre 21, 35 36 68 81 although higher recommended minimum levels have been recently introduced 48 (discussed later in more detail). The majority of guidelines also state that cryoprecipitate should only be administered in the presence of clinical bleeding. 35 36 68 81 In the USA, Canada, the UK, and Australia, guidelines are in agreement that cryoprecipitate should not be used to treat von Willebrand disease or haemophilia A, or may only be considered if virus-inactivated factor concentrates or recombinant factor preparations are unavailable ( Table 2) . The preference for use of factor concentrates over allogeneic blood products is also beginning to emerge in guidelines for the treatment of afibrinogenaemia. Recently, guidelines from the Association of Anaesthetists of Great Britain and Northern Ireland have stated that cryoprecipitate should only be used to treat established coagulopathy if fibrinogen concentrate is unavailable, as fibrinogen replacement can be achieved more rapidly and predictably with fibrinogen concentrate. 84 
Dosing strategies
Cryoprecipitate is indicated for use in acquired hypofibrinogenaemia and is administered in a wide range of clinical settings, the most common of which is cardiac surgery, accounting for 32-45% of all transfusions. 16 34 91 A report from the UK estimated that 95% of cryoprecipitate given during cardiac surgery was administered in response to haemorrhage and not given prophylactically. 34 Cryoprecipitate is also commonly given to trauma (12 -29%) and non-cardiac surgery (12-13%) patients, 16 34 91 and to patients in other clinical scenarios including obstetrics, liver failure, oncology, and gastrointestinal bleeding. 16 34 91 It is also commonly used in acute promyelocytic leukaemia, where fibrinogen supplementation with cryoprecipitate is recommended to target a plasma fibrinogen level of 1-2 g litre 21 in coagulopathic patients. 82 85 Despite similar recommended doses (as described above) and annual use [e.g. 2.0 U per 1000 people annually in the UK (126 170 U 73 /62 million people) and 1. The indications for cryoprecipitate have been developed in guidelines by some professional societies ( Table 2) . As described in the Circular of Information for Blood and Blood Components 13 and licensed by the FDA, use of cryoprecipitate is specified for patients with acquired hypofibrinogenaemia, which is almost always seen in acquired coagulopathies.
In the course of transfusion, it is given almost exclusively after RBCs, FFP, and platelets. In a study of cryoprecipitate use in Canadian hospitals, a mean dose of 7.9 U was administered per patient across all clinical settings; however, cryoprecipitate was only administered after transfusion of an average of 10.5 U RBCs, 6.5 U plasma, and 9.4 U platelet concentrate.
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A recent study of 1238 trauma patients found that the median time from admission to first administration of cryoprecipitate was 2.8 h (inter-quartile range, 1.7-4.5 h); this is essentially very late, given that the median time to death from haemorrhage in this study was 2.6 h. 45 93 In addition, a study in New Zealand found that under-dosing of cryoprecipitate was far more common than overdosing. 94 95 and an audit of Canadian hospitals reported that the majority of cryoprecipitate use is not in accordance with published guidelines. 16 A study in the USA involving 88 transfusions of cryoprecipitate in 51 patients found that 20% of cryoprecipitate used during the study period was administered for inappropriate indications. 28 Moreover, in a survey of cryoprecipitate use in UK hospitals, cryoprecipitate was administered to 101/423 patients without prior assessment of fibrinogen levels (i.e. given 'blind'). 34 Finally, an audit in Canada found that 9 of 25 hospitals did not have transfusion guidelines for cryoprecipitate in place. 16 In these hospitals, cryoprecipitate was more likely to be administered inappropriately, demonstrating the importance of clear transfusion guidelines. Currently, many guidelines and massive transfusion protocols recommend administering cryoprecipitate for plasma fibrinogen levels of ,1.0 g litre 21 ; however, this threshold is not based on solid clinical evidence (discussed in more detail in a recent review by Levy and colleagues). 79 Recent recommendations suggest that higher target plasma fibrinogen levels may be more appropriate; 48 84 96 for example, the European Trauma Guidelines, which recommend supplementation for fibrinogen levels of ,1. Point-of-care monitoring
Most guidelines recommend that cryoprecipitate be administered in response to fibrinogen levels decreasing below a certain threshold; however, in an emergency setting, turnaround times for the Clauss fibrinogen assay are too long to effectively guide administration of haemostatic therapy in patients with acquired coagulopathic bleeding. In an attempt to address this issue, Chandler and colleagues proposed a revised fibrinogen assay in their emergency haemorrhage panel. 97 The revised assay resulted in emergency coagulation testing turnaround times for fibrinogen levels of ,20 min for the majority of cases. Furthermore, viscoelastic methods such as ROTEM and thrombelastography (TEG) can be performed at the bedside and provide rapid assessment of multiple coagulation parameters. For each of these methods, a specific fibrin test is available (FIBTEM and the functional fibrinogen test, respectively). Point-of-care monitoring may prevent over-and under-dosing, potentially reducing side effects and costs while ensuring that patients are given sufficient coagulation therapy. Point-of-care tests are effective for guiding targeted haemostatic therapy; there is growing evidence that their use is associated with lower transfusion requirements for allogeneic blood products in a variety of clinical settings. 98 -102 In addition, a favourable survival rate was observed in patients administered with fibrinogen concentrate with or without prothrombin complex concentrate guided by ROTEM. 103 Although there is a growing body of literature on the use of viscoelastic tests to guide the administration of coagulation factor concentrates, few studies have been published on their use to guide administration of cryoprecipitate. 25 43 64 104 In an audit of cryoprecipitate transfusion in the UK, point-of-care testing was used in only 11% of patients. 34 Although point-of-care testing facilitates rapid diagnosis of coagulopathy, cryoprecipitate is not quickly available as it must be ordered from the blood bank, thawed and pooled, which can take 25-45 min. 16 Even if cryoprecipitate has been preordered, it takes 30 min to infuse a standard dose of two pools. In contrast, fibrinogen concentrate is reconstituted as a smaller volume, which allows large doses to be administered in a few minutes. 103 In cases of severe bleeding, it has been reported that it is possible to infuse 1 g fibrinogen concentrate in 20 s. 105 Importantly, cryoprecipitate also contains varying concentrations of fibrinogen (Table 1) and is not as suitable as fibrinogen concentrate for targeted dosing.
Cost
Cost is highly influential in decision-making policies. Cryoprecipitate is generally perceived as being cheaper than fibrinogen concentrate; however, the true cost of blood products such as cryoprecipitate is higher than the direct acquisition cost of the drug: indirect costs must also be taken into account. Following manufacture, indirect costs include storage, preparation, thawing, processing, and compatibility testing. Moreover, blood products are wasted if they cannot be used as planned, 106 and haemovigilance schemes must be maintained. Transfusion of cryoprecipitate is also affected by the cost of treating adverse events 107 108 and infectious disease associated with transfusion. 109 Methylene blue-treated cryoprecipitate undergoes viral inactivation and therefore may avoid some of these costs, but the acquisition cost is higher than that of fibrinogen concentrate. 77 In addition, transfusion of allogeneic blood products is associated with mortality caused by TRALI and TACO, 110 longer hospital stays and increased healthcare costs. 111 To date, the true cost of cryoprecipitate has not been calculated.
Future directions
Further developments may address one of the main concerns regarding the use of cryoprecipitate, namely the risk of pathogen transmission. Pathogen inactivation steps have previously been described for the production of FFP, 112 and recent studies have described the production of cryoprecipitate from plasma treated with riboflavin and UV light, 113 amotosalen and UV light 114 and solvent-detergent filtration. 115 However, as with pathogen-inactivated FFP, these products have reduced levels of coagulation factors, with 35% less fibrinogen than standard plasma. 113 114 A retrospective analysis found that introduction of methylene blue-inactivated plasma led to an increase in demand for plasma and cryoprecipitate. 116 In addition, extra steps during production also add to the cost, although these may be offset by a reduction in the cost of treating adverse events. 117 Fibrinogen concentrate may provide a favourable alternative to cryoprecipitate, such as is currently practiced in most of the EU. It can be stored at room temperature, is readily available for use, and is easy to reconstitute and administer. Fibrinogen concentrate also undergoes virus removal and inactivation steps, which have been shown to be effective against both enveloped and non-enveloped viruses. 76 These steps additionally remove antibodies and antigens, greatly reducing the risk of immunological and allergic reactions. Results from recent clinical studies show promising efficacy of fibrinogen concentrate in various clinical settings. 69 98 100 105 118 Further studies are required to confirm and support the existing data on the efficacy and safety of fibrinogen concentrate. Current guidelines specify that coagulation factor concentrates should be used in preference to cryoprecipitate for the treatment of haemophilia A and von Willebrand disease because of safety reasons 13 86 -89 (Table 2) . Although fibrinogen concentrate is now used as a first-line haemostatic BJA Nascimento et al.
treatment for acquired hypofibrinogenaemia in some European countries, it is licensed only for congenital afibrinogenaemia/hypofibrinogenaemia in other countries including the USA. Thus, local licensing and availability largely dictates in which countries cryoprecipitate and fibrinogen concentrate are used. It is anticipated that further evidence from highquality trials will inform local licensure and treatment guidelines in the future. 80 
Conclusion
Despite the acceptance of cryoprecipitate for fibrinogen supplementation in acquired coagulopathy in many countries, there remains a lack of Level 1 evidence to support its use. In addition, there is undoubtedly inappropriate administration of cryoprecipitate. As with all allogeneic blood products, cryoprecipitate carries a risk of pathogen transmission and transfusion-associated adverse events. There is a need for prospective, randomized, controlled clinical trials to determine the haemostatic efficacy of cryoprecipitate compared with the efficacy of alternative preparations. It is anticipated that these trials will lead to the production of evidence-based guidelines to inform physicians and guide clinical practice.
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